308 related articles for article (PubMed ID: 17999701)
1. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors.
Tao J; Li Y; Liu YQ; Li L; Liu J; Shen X; Shen GX; Tu YT
Br J Dermatol; 2008 Jan; 158(1):88-94. PubMed ID: 17999701
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity.
Tao J; Li Y; Liu YQ; Wang L; Yang J; Dong J; Wu Y; Shen GX; Tu YT
J Invest Dermatol; 2008 Aug; 128(8):1991-6. PubMed ID: 18385764
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
Kageshita T; Hirai S; Ono T; Hicklin DJ; Ferrone S
Am J Pathol; 1999 Mar; 154(3):745-54. PubMed ID: 10079252
[TBL] [Abstract][Full Text] [Related]
4. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
Vitale M; Rezzani R; Rodella L; Zauli G; Grigolato P; Cadei M; Hicklin DJ; Ferrone S
Cancer Res; 1998 Feb; 58(4):737-42. PubMed ID: 9485029
[TBL] [Abstract][Full Text] [Related]
5. Identification of domain boundaries within the N-termini of TAP1 and TAP2 and their importance in tapasin binding and tapasin-mediated increase in peptide loading of MHC class I.
Procko E; Raghuraman G; Wiley DC; Raghavan M; Gaudet R
Immunol Cell Biol; 2005 Oct; 83(5):475-82. PubMed ID: 16174096
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
Seliger B; Atkins D; Bock M; Ritz U; Ferrone S; Huber C; Störkel S
Clin Cancer Res; 2003 May; 9(5):1721-7. PubMed ID: 12738726
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.
Kovalcsik E; John J; Turner M; Birchall L; Sage D; Whittle R; Dalgleish A; Pandha H
Melanoma Res; 2004 Dec; 14(6):463-71. PubMed ID: 15577316
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing.
Hicklin DJ; Kageshita T; Ferrone S
Tissue Antigens; 1996 Jul; 48(1):38-46. PubMed ID: 8864173
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
10. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.
Thor Straten P; Kirkin AF; Seremet T; Zeuthen J
Int J Cancer; 1997 Mar; 70(5):582-6. PubMed ID: 9052759
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.
Kasajima A; Sers C; Sasano H; Jöhrens K; Stenzinger A; Noske A; Buckendahl AC; Darb-Esfahani S; Müller BM; Budczies J; Lehman A; Dietel M; Denkert C; Weichert W
Hum Pathol; 2010 Dec; 41(12):1758-69. PubMed ID: 20869097
[TBL] [Abstract][Full Text] [Related]
12. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression.
Dissemond J; Götte P; Mörs J; Lindeke A; Goos M; Ferrone S; Wagner SN
Melanoma Res; 2003 Jun; 13(3):253-8. PubMed ID: 12777979
[TBL] [Abstract][Full Text] [Related]
13. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
[TBL] [Abstract][Full Text] [Related]
14. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
15. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
16. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.
Müller M; Agaimy A; Zenk J; Ettl T; Iro H; Hartmann A; Seliger B; Schwarz S
Histopathology; 2013 May; 62(6):847-59. PubMed ID: 23611358
[TBL] [Abstract][Full Text] [Related]
18. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
Vitale M; Pelusi G; Taroni B; Gobbi G; Micheloni C; Rezzani R; Donato F; Wang X; Ferrone S
Clin Cancer Res; 2005 Jan; 11(1):67-72. PubMed ID: 15671529
[TBL] [Abstract][Full Text] [Related]
19. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
Seliger B; Ritz U; Abele R; Bock M; Tampé R; Sutter G; Drexler I; Huber C; Ferrone S
Cancer Res; 2001 Dec; 61(24):8647-50. PubMed ID: 11751378
[TBL] [Abstract][Full Text] [Related]
20. [Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in laryngeal squamous cell carcinoma].
Zeng Q; Wang XL; Xu ZG; Lü N; Zheng S; Zhao QZ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Mar; 47(3):234-40. PubMed ID: 22805026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
